PBYI
PUMA BIOTECHNOLOGY, INC.
Key Financials
Operating Income
$37.3M
↑ 20.5%
Revenue
$228.4M
↓ 0.9%
Net Income
$31.1M
↑ 2.8%
Total Assets
$216.3M
↑ 1.4%
Total Liabilities
$86.0M
↓ 29.1%
Cash & Equivalents
$29.6M
↓ 57.2%
EPS (Diluted)
$0.61
↓ 1.6%
Shareholders' Equity
$130.3M
↑ 41.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| DEFA14A | 4/28/2026 | View on SEC |
| ARS | 4/28/2026 | View on SEC |
| DEF 14A | 4/28/2026 | View on SEC |
| PRE 14A | 4/7/2026 | View on SEC |
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
| 10-K | 2/26/2026 | View on SEC |
| 8-K | 2/26/2026 | View on SEC |
| 4 | 2/20/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PBYI |
| Company Name | PUMA BIOTECHNOLOGY, INC. |
| CIK | 1401667 |
| Sector | Pharmaceutical Preparations |
| Industry | Accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (424) 248-6500 |